Helix Pharma (Pvt)., Ltd.
Private pharmaceutical manufacturer · Karachi · Pakistan
Karachi pharmaceutical manufacturer with a history dating to 1960 and a broad prescription and consumer-health portfolio.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Legal / official name
- Helix Pharma (Pvt.) Limited
- Company type
- Private pharmaceutical manufacturer
- Address
- A-56 Manghopir Road, Metroville, S.I.T.E., Karachi, Pakistan
- Website
- helix-ph.com ↗
- Phone
- +92 21 111 475 475
- Official contact
- Contact page ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 88%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| Hilixophin | Ceftriaxone | 1 g | Injection | 1's | 107485 | PKR 670.58 | PKR 670.58/vial/unit | 12% above median |
| Hipro | Ciprofloxacin | 250 mg | Tablet | 1x10’s | 014877 | PKR 367.99 | PKR 36.80/tablet | 46% above median |
| Hipro | Ciprofloxacin | 500 mg | Tablet | 1x10’s | 019750 | PKR 661.24 | PKR 66.12/tablet | 55% above median |
| Hipro | Ciprofloxacin | 100 mg | Tablet | 10's | 061101 | PKR 86.29 | PKR 8.63/tablet | 12% below median |
| Hipro | Ciprofloxacin | 750 mg | Tablet | 10's | 061102 | PKR 310.64 | PKR 31.06/tablet | 22% below median |
| Hipro XR | Ciprofloxacin | 1000 mg | Extended-release tablet | 10's | 076440 | PKR 723.48 | PKR 72.35/tablet | 28% above median |
| Hitac | Ranitidine | 150 mg | Tablet | 1x10's | 010919 | PKR 152.21 | PKR 15.22/tablet | 36% above median |
| Hitaxime | Cefotaxime | 250 mg | Injection | 1's | 107486 | PKR 110.89 | PKR 110.89/vial/unit | 5% above median |
| Hitaxime | Cefotaxime | 500 mg | Injection | 1's | 107487 | PKR 167.12 | PKR 167.12/vial/unit | Near median |
| Hitaxime | Cefotaxime | 1 g | Injection | 1's | 107488 | PKR 300.58 | PKR 300.58/vial/unit | Near median |
| Hitazidime | Ceftazidime | 500 mg | IV/IM injection | 1's | 105493 | PKR 255.32 | PKR 255.32/vial/unit | 5% above median |
| Hitazidime | Ceftazidime | 1000 mg | Injection | 1's | 105494 | PKR 479.57 | PKR 479.57/vial/unit | 5% above median |
| Hitazidime | Ceftazidime | 250 mg | Injection | 1's | 105495 | PKR 167.85 | PKR 167.85/vial/unit | Near median |
| Hixopenem | Meropenem | 500 mg | IV injection | 1's | 118371 | PKR 2,209.88 | PKR 2,209.88/vial/unit | 6% above median |
| Hixopenem | Meropenem | 1 g | Injection | 1's | 118372 | PKR 4,130.61 | PKR 4,130.61/vial/unit | 6% above median |
| Ironal | Iron polymaltose complex | 100 mg | Tablet | 3x10’s | 030286 | PKR 349.47 | PKR 11.65/tablet | 19% below median |
| Ironal | Iron polymaltose complex | 50 mg/5 mL | Syrup | 60ml | 030603 | PKR 174.74 | PKR 2.91/mL | 26% above median |
| Ironal | Iron polymaltose complex | 50 mg/5 mL | Syrup | 120ml | 030603 | PKR 330.06 | PKR 2.75/mL | 19% above median |
| Ironal-F | Iron polymaltose complex + Folic acid | 100 mg + 0.35 mg | Tablet | 3x10’s | 030287 | PKR 407.72 | PKR 13.59/tablet | Near median |
| Mether | Artemether | 40 mg | Injection | 10's | 061541 | PKR 1,189.29 | PKR 118.93/vial/unit | Near median |
| Misolix | Misoprostol | 200 mcg | Tablet | 28's | 114776 | PKR 578.29 | PKR 20.65/tablet | Near median |
| Misolix | Misoprostol | 200 mcg | Tablet | 10's | 114776 | PKR 206.53 | PKR 20.65/tablet | Near median |
| Misolix | Misoprostol | 100 mcg | Tablet | 10's | 114777 | PKR 123.92 | PKR 12.39/tablet | Near median |
| Neu peg PF S | Pegfilgrastim | 6 mg/0.6 mL | Prefilled syringe injection | 1's | 107884 | PKR 72,482.79 | PKR 72,482.79/syringe | 15% above median |
| Oflocin Ear | Ofloxacin | 0.3 % | Ear drops | 5ml | 024440 | PKR 138.75 | PKR 27.75/mL | 7% below median |
| Oflocin Ear | Ofloxacin | 0.6 % | Ear drops | 5ml | 024441 | PKR 237.86 | PKR 47.57/mL | 7% below median |
| Oxol | Oxaliplatin | 100 mg/50 mL (2 mg/mL) | Injection | 1's | 072515 | PKR 36,931.71 | PKR 36,931.71/vial/unit | No comparator |
| Oxol | Oxaliplatin | 50 mg/25 mL | Injection | 1's | 072516 | PKR 18,465.85 | PKR 18,465.85/vial/unit | Near median |
| Recept | Risperidone | 2 mg | Tablet | 3x10’s | 030598 | PKR 970.75 | PKR 32.36/tablet | 13% below median |
| Recept | Risperidone | 2 mg | Tablet | 1x10’s | 030598 | PKR 465.96 | PKR 46.60/tablet | 27% above median |
| Recept | Risperidone | 4 mg | Tablet | 1x10’s | 030599 | PKR 679.52 | PKR 67.95/tablet | 7% below median |
| Recept | Risperidone | 1 mg | Tablet | 1x10’s | 035442 | PKR 232.98 | PKR 23.30/tablet | Near median |
| Recept | Risperidone | 3 mg | Tablet | 1x10’s | 035443 | PKR 543.62 | PKR 54.36/tablet | 7% below median |
| Relicitabine | Capecitabine | 500 mg | Tablet | 120's | 088875 | PKR 39,239.94 | PKR 327.00/tablet | 8% below median |
| Relicitabine | Capecitabine | 150 mg | Tablet | 120's | 088876 | PKR 16,951.65 | PKR 141.26/tablet | No comparator |
| Relidomide | Lenalidomide | 5 mg | Capsule | 7's | 110579 | PKR 3,029.87 | PKR 432.84/capsule | Near median |
| Relidomide | Lenalidomide | 5 mg | Capsule | 10's | 110579 | PKR 4,327.96 | PKR 432.80/capsule | Near median |
| Relidomide | Lenalidomide | 5 mg | Capsule | 21's | 110579 | PKR 9,089.61 | PKR 432.84/capsule | Near median |
| Relidomide | Lenalidomide | 10 mg | Capsule | 7's | 110580 | PKR 5,321.41 | PKR 760.20/capsule | Near median |
| Relidomide | Lenalidomide | 10 mg | Capsule | 10's | 110580 | PKR 7,602.44 | PKR 760.24/capsule | Near median |
| Relidomide | Lenalidomide | 10 mg | Capsule | 21's | 110580 | PKR 15,967.22 | PKR 760.34/capsule | Near median |
| Relidomide | Lenalidomide | 25 mg | Capsule | 7's | 110581 | PKR 11,723.30 | PKR 1,674.76/capsule | Near median |
| Relidomide | Lenalidomide | 25 mg | Capsule | 10's | 110581 | PKR 16,747.58 | PKR 1,674.76/capsule | Near median |
| Relidomide | Lenalidomide | 25 mg | Capsule | 21's | 110581 | PKR 35,171.41 | PKR 1,674.83/capsule | Near median |
| Robol | Doxorubicin | 10 mg/5 mL | Injection | 1's | 072510 | PKR 769.96 | PKR 769.96/vial/unit | Near median |
| Robol | Doxorubicin | 50 mg/25 mL | Injection | 1's | 072511 | PKR 2,458.65 | PKR 2,458.65/vial/unit | 20% below median |
| Sedol | Etoposide | 100 mg/5 mL (20 mg/mL) | Injection | 1's | 072509 | PKR 815.57 | PKR 815.57/vial/unit | No comparator |
| Sofotel | Sofosbuvir | 400 mg | Tablet | 28's | 083090 | PKR 11,392.72 | PKR 406.88/tablet | 6% below median |
| Tavelor | Loratadine | 5 mg/5 mL | Suspension | 60 ml | 027025 | PKR 103.55 | PKR 1.73/mL | 13% below median |
| Tavelor | Loratadine | 5 mg/5 mL | Suspension | 30 ml | 027025 | PKR 60.40 | PKR 2.01/mL | 10% above median |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.